353 related articles for article (PubMed ID: 34771622)
1. Radionuclide-Based Imaging of Breast Cancer: State of the Art.
Li H; Liu Z; Yuan L; Fan K; Zhang Y; Cai W; Lan X
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771622
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET.
Stoykow C; Erbes T; Maecke HR; Bulla S; Bartholomä M; Mayer S; Drendel V; Bronsert P; Werner M; Gitsch G; Weber WA; Stickeler E; Meyer PT
Theranostics; 2016; 6(10):1641-50. PubMed ID: 27446498
[TBL] [Abstract][Full Text] [Related]
4. Molecular imaging of breast cancer.
Oude Munnink TH; Nagengast WB; Brouwers AH; Schröder CP; Hospers GA; Lub-de Hooge MN; van der Wall E; van Diest PJ; de Vries EG
Breast; 2009 Oct; 18 Suppl 3():S66-73. PubMed ID: 19914546
[TBL] [Abstract][Full Text] [Related]
5. The association of 18F-fluorodeoxyglucose PET/computed tomography parameters with tissue gastrin-releasing peptide receptor and integrin αvβ3 receptor levels in patients with breast cancer.
Arslan E; Aksoy T; Can Trabulus FD; Kelten Talu C; Yeni B; Çermik TF
Nucl Med Commun; 2020 Mar; 41(3):260-268. PubMed ID: 31895261
[TBL] [Abstract][Full Text] [Related]
6. Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis.
Henry KE; Ulaner GA; Lewis JS
PET Clin; 2017 Jul; 12(3):269-288. PubMed ID: 28576166
[TBL] [Abstract][Full Text] [Related]
7. Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides.
Ge S; Li J; Yu Y; Chen Z; Yang Y; Zhu L; Sang S; Deng S
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770887
[TBL] [Abstract][Full Text] [Related]
8. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.
Yoon HJ; Kang KW; Chun IK; Cho N; Im SA; Jeong S; Lee S; Jung KC; Lee YS; Jeong JM; Lee DS; Chung JK; Moon WK
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1534-43. PubMed ID: 24652232
[TBL] [Abstract][Full Text] [Related]
9. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
10. Review: Receptor Targeted Nuclear Imaging of Breast Cancer.
Dalm SU; Verzijlbergen JF; De Jong M
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134770
[TBL] [Abstract][Full Text] [Related]
11. Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals.
Ananias HJ; de Jong IJ; Dierckx RA; van de Wiele C; Helfrich W; Elsinga PH
Curr Pharm Des; 2008; 14(28):3033-47. PubMed ID: 18991717
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in imaging endogenous or transferred gene expression utilizing radionuclide technologies in living subjects: applications to breast cancer.
Berger F; Gambhir SS
Breast Cancer Res; 2001; 3(1):28-35. PubMed ID: 11250742
[TBL] [Abstract][Full Text] [Related]
13. Molecular imaging probes for diagnosis and therapy evaluation of breast cancer.
Meng Q; Li Z
Int J Biomed Imaging; 2013; 2013():230487. PubMed ID: 23533377
[TBL] [Abstract][Full Text] [Related]
14. Molecular imaging using PET and SPECT for identification of breast cancer subtypes.
Liu H; Chen Y; Wu S; Song F; Zhang H; Tian M
Nucl Med Commun; 2016 Nov; 37(11):1116-24. PubMed ID: 27438531
[TBL] [Abstract][Full Text] [Related]
15. Development of the Tumor-Specific Antigen-Derived Synthetic Peptides as Potential Candidates for Targeting Breast and Other Possible Human Carcinomas.
Okarvi SM; AlJammaz I
Molecules; 2019 Aug; 24(17):. PubMed ID: 31470531
[TBL] [Abstract][Full Text] [Related]
16. From Bench to Bed: New Gastrin-Releasing Peptide Receptor-Directed Radioligands and Their Use in Prostate Cancer.
Maina T; Nock BA
PET Clin; 2017 Apr; 12(2):205-217. PubMed ID: 28267454
[TBL] [Abstract][Full Text] [Related]
17. Progesterone receptor targeting with radiolabelled steroids: an approach in predicting breast cancer response to therapy.
Cunha S; Gano L; Morais GR; Thiemann T; Oliveira MC
J Steroid Biochem Mol Biol; 2013 Sep; 137():223-41. PubMed ID: 23669457
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples.
Morgat C; Schollhammer R; Macgrogan G; Barthe N; Vélasco V; Vimont D; Cazeau AL; Fernandez P; Hindié E
PLoS One; 2019; 14(1):e0210905. PubMed ID: 30645633
[TBL] [Abstract][Full Text] [Related]
19. Molecular Imaging of Breast Cancer: Role of RGD Peptides.
Chakravarty R; Chakraborty S; Dash A
Mini Rev Med Chem; 2015; 15(13):1073-94. PubMed ID: 26349490
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer.
Dalm SU; Martens JW; Sieuwerts AM; van Deurzen CH; Koelewijn SJ; de Blois E; Maina T; Nock BA; Brunel L; Fehrentz JA; Martinez J; de Jong M; Melis M
J Nucl Med; 2015 May; 56(5):752-7. PubMed ID: 25791989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
